Publication date: 2 October 2026 Source: Progress in Neuro-Psychopharmacology and Biological Psychiatry, Volume 150 Author(s): Elizabeth A. Virakorn, Kathryn D. Baker, Rick Richardson
Fluoxetine enhances the retention of fear extinction in corticosterone-exposed male adolescent rats. // Progress in Neuro-Psychopharmacology & Biological Psychiatry. – URL: https://www.sciencedirect.com/science/article/pii/S0278584626003374?dgcid=rss_sd_all
Fluoxetine enhances the retention of fear extinction in corticosterone-exposed male adolescent rats. Progress in Neuro-Psychopharmacology & Biological Psychiatry. https://www.sciencedirect.com/science/article/pii/S0278584626003374?dgcid=rss_sd_all
“Fluoxetine enhances the retention of fear extinction in corticosterone-exposed male adolescent rats.” Progress in Neuro-Psychopharmacology & Biological Psychiatry.
@article{article119402,
title = {Fluoxetine enhances the retention of fear extinction in corticosterone-exposed male adolescent rats},
journal = {Progress in Neuro-Psychopharmacology \& Biological Psychiatry},
url = {https://www.sciencedirect.com/science/article/pii/S0278584626003374?dgcid=rss_sd_all}
}
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01953-z IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01958-8 Artificial intelligence aids multi-omics data integration in cancer drug discovery and development: from targets to drug synergy
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00179-2 The NIH’s P. J. Brooks discusses the challenges and opportunities ahead for gene therapies and gene editing for diseases of no commercial interest.
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00181-8 Merck and Moderna’s intismeran autogene succeeded in a landmark melanoma trial, but the oncology community still has more questions than...